Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

MAIN PURPOSE: Voreloxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, inducing site-selective DNA damage. Voreloxin is in clinical studies, as a single agent and in combination with cytarabine, for the treatment of acute myeloid leukemia (AM...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Scatena, Caroline D., Kumer, Jeffrey L., Arbitrario, Jennifer P., Howlett, Anthony R., Hawtin, Rachael E., Fox, Judith A., Silverman, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer-Verlag 2010
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2921053/
https://ncbi.nlm.nih.gov/pubmed/20058009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-009-1234-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados